SCHEMBL31291103

SCHEMBL31291103

CC(C)(C)NC[C@H](O)c1ccc(Cl)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 4/20 0.50
LMNA P02545 4/20 0.50
ADRB2 P07550 6/20 0.49
ADRB1 P08588 4/20 0.49
CYP2D6 P10635 2/20 0.49
NFKB1 P19838 2/20 0.49
BLM P54132 1/20 0.48
TSHR P16473 3/20 0.44
HTR1A P08908 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
ADRA1A P35348 1/20 0.44
OPRK1 P41145 1/20 0.44
SLC6A3 Q01959 1/20 0.44
CYP3A4 P08684 2/20 0.43
KDM4E B2RXH2 1/20 0.43
KMT2A Q03164 2/20 0.43
CYP2C9 P11712 1/20 0.41
CASP7 P55210 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20819349 1.00 HIF1A (0.50) HIF1ALMNAADRB2ADRB1CYP2D6
SCHEMBL20819357 1.00 HIF1A (0.50) HIF1ALMNAADRB2ADRB1CYP2D6
Hydrochloric Acid SCHEMBL20819397 0.98 BLM (0.50) HIF1ALMNAADRB2ADRB1CYP2D6
Hydrochloric Acid SCHEMBL20819398 0.98 BLM (0.50) HIF1ALMNAADRB2ADRB1CYP2D6
SCHEMBL24302759 0.86 HIF1A (0.38) HIF1ALMNAADRB2ADRB1CYP2D6
SCHEMBL22481311 0.83 HIF1A (0.51) HIF1ALMNAADRB2ADRB1CYP2D6
SCHEMBL22481252 0.83 HIF1A (0.51) HIF1ALMNAADRB2ADRB1CYP2D6
SCHEMBL20819384 0.83 HIF1A (0.55) HIF1ALMNAADRB2ADRB1CYP2D6
SCHEMBL10841508 0.83 HIF1A (0.55) HIF1ALMNAADRB2ADRB1CYP2D6
SCHEMBL31291101 0.83 HIF1A (0.55) HIF1ALMNAADRB2ADRB1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240398770-A1 HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA ATROGI AB (SE) 2024-12-05 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240398770-A1 HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA SLC5A2, SLC5A1, GPR119 HIF1A 688/4885LMNA 2140/4885ADRB2 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.